- Home
- EDUC vs INAB Comparison
EDUC vs INAB Comparison
Compare EDUC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDUC | INAB |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDUC | INAB |
|---|---|---|
| Price | $1.45 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | 20.0K | ★ 719.5K |
| Earning Date | 01-08-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $25,371,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $1.17 |
| 52 Week High | $1.91 | $12.53 |
Technical Indicators
Market Signals| Indicator | EDUC | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 62.14 |
| Support Level | $1.23 | $2.15 |
| Resistance Level | $1.39 | $2.59 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 87.50 | 83.92 |
Price Performance
Historical ComparisonAbout EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.